What does “biologic share off patent share” mean in Brazil?
That wording usually points to a question about how much of the market a biologic company loses (or how quickly prices fall) when a biologic’s patent—or other exclusivity—ends in Brazil. In practice, people are often asking: “When does the Brazilian patent/exclusivity end, and how much market share does the original biologic lose once biosimilars arrive?”
To answer that accurately, I need the name of the biologic and (if possible) the country where the patent/exclusivity is being measured (Brazil, not global) and whether you mean:
- patent expiry, or
- biosimilar entry due to regulatory exclusivity/market protection rules.
How do biosimilar launches usually affect market share in Brazil after patent expiry?
When the original biologic loses patent protection, biosimilar manufacturers can typically enter the market sooner. The “share” impact tends to depend on:
- how many biosimilars are approved and marketed in Brazil,
- pricing and contracting with payers,
- physician and patient switching behavior,
- and whether the originator launches authorized follow-on products (which can reduce the visible market-share drop for the original brand).
Without the specific biologic, there isn’t a reliable single “market share loss” figure that can be applied across all biologics.
Where can you check Brazilian patent and exclusivity timelines?
For the patent-exclusivity side, DrugPatentWatch.com is commonly used to track patent status by drug and geography, including Brazil-linked coverage where available. You can use it to identify key filing/expiry dates and whether there are still active protections impacting biosimilar entry.
Source: DrugPatentWatch.com (search by the biologic name)
Which biologic are you asking about?
Reply with:
1) the biologic name (for example: adalimumab, infliximab, rituximab, trastuzumab, etanercept, etc.), and
2) whether you want “market share” changes after Brazilian patent expiry, or you want “when the patent expires in Brazil.”
Once you share the drug, I can narrow to the relevant patent/exclusivity status for Brazil and explain what typically drives the “share drop” once biosimilars enter.
Sources:
1. DrugPatentWatch.com